Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A Meta-Analysis

Zhenchang Wang; Yunjie Duan; Jinmei Zhang; Yanhang Lv; Shanshan Wu; Mingrong  Cheng; Akshaya Srikanth Bhagavathula; Wafa  Ali Aldhaleei; Cain Clark; Zongwei Huo

doi:10.1016/j.ejphar.2020.173382

Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A Meta-Analysis

Zhenchang Wang, Yunjie Duan, Jinmei Zhang, Yanhang Lv, Shanshan Wu, Mingrong Cheng, Akshaya Srikanth Bhagavathula, Wafa Ali Aldhaleei, Cain Clark, Zongwei Huo

Research output: Contribution to journal › Review article › peer-review

2 Downloads (Pure)

Abstract

Microvascular invasion (MVI) is an important predictor of metastatic tumour recurrence and is associated with adverse outcomes and poor prognosis in Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. The association between varying regimens of anti-viral drugs with the incidence of MVI in HBV-related HCC has been demonstrated, however, no meta-analysis of the available data has been conducted. Therefore, the current study sought to evaluate the association of preoperative antiviral therapy with incidence of microvascular invasion in HCC hepatitis virus patients. A systematic search of the literature was performed in MEDLINE/PubMed, Web of Science (WoS), and Scopus, up to January 2020. A random-effects model was used to estimate pooled odds ratios (ORs). Overall, six studies, with 4988 patients, met our inclusion criteria. The pooled OR of MVI in the patients who had preoperative antiviral therapy versus the patients who did not have antiviral therapy was; OR: 0.60, 95% Confidence Interval (CI): 0.49–0.73; I ² = 25%. In this study, a significant reduction in the OR of MVI was evident in patients who had anti-viral therapy.

Original language	English
Article number	173382
Journal	European Journal of Pharmacology
Volume	883
Early online date	18 Jul 2020
DOIs	https://doi.org/10.1016/j.ejphar.2020.173382
Publication status	Published - 15 Sep 2020

Bibliographical note

NOTICE: this is the author’s version of a work that was accepted for publication in European Journal of Pharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in European Journal of Pharmacology, 883, (2020)
DOI: 10.1016/j.ejphar.2020.173382

© 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords

Anti-viral therapy
Hepatitis B
Hepatocellular carcinoma
Microvascular invasion

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/j.ejphar.2020.173382

Post-PrintAccepted author manuscript, 205 KBLicence: CC BY-NC-ND

Cite this

Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma : A Meta-Analysis. / Wang, Zhenchang; Duan, Yunjie; Zhang, Jinmei; Lv, Yanhang; Wu, Shanshan; Cheng, Mingrong ; Bhagavathula, Akshaya Srikanth; Ali Aldhaleei, Wafa ; Clark, Cain; Huo, Zongwei.

In: European Journal of Pharmacology, Vol. 883, 173382, 15.09.2020.

Research output: Contribution to journal › Review article › peer-review

@article{21c09477e0534f5b8771247e3b847dfa,

title = "Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A Meta-Analysis",

abstract = "Microvascular invasion (MVI) is an important predictor of metastatic tumour recurrence and is associated with adverse outcomes and poor prognosis in Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. The association between varying regimens of anti-viral drugs with the incidence of MVI in HBV-related HCC has been demonstrated, however, no meta-analysis of the available data has been conducted. Therefore, the current study sought to evaluate the association of preoperative antiviral therapy with incidence of microvascular invasion in HCC hepatitis virus patients. A systematic search of the literature was performed in MEDLINE/PubMed, Web of Science (WoS), and Scopus, up to January 2020. A random-effects model was used to estimate pooled odds ratios (ORs). Overall, six studies, with 4988 patients, met our inclusion criteria. The pooled OR of MVI in the patients who had preoperative antiviral therapy versus the patients who did not have antiviral therapy was; OR: 0.60, 95% Confidence Interval (CI): 0.49–0.73; I 2 = 25%. In this study, a significant reduction in the OR of MVI was evident in patients who had anti-viral therapy. ",

keywords = "Anti-viral therapy, Hepatitis B, Hepatocellular carcinoma, Microvascular invasion",

author = "Zhenchang Wang and Yunjie Duan and Jinmei Zhang and Yanhang Lv and Shanshan Wu and Mingrong Cheng and Bhagavathula, {Akshaya Srikanth} and {Ali Aldhaleei}, Wafa and Cain Clark and Zongwei Huo",

note = "NOTICE: this is the author{\textquoteright}s version of a work that was accepted for publication in European Journal of Pharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in European Journal of Pharmacology, 883, (2020) DOI: 10.1016/j.ejphar.2020.173382 {\textcopyright} 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ ",

year = "2020",

month = sep,

day = "15",

doi = "10.1016/j.ejphar.2020.173382",

language = "English",

volume = "883",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier",

}

TY - JOUR

T1 - Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma

T2 - A Meta-Analysis

AU - Wang, Zhenchang

AU - Duan, Yunjie

AU - Zhang, Jinmei

AU - Lv, Yanhang

AU - Wu, Shanshan

AU - Cheng, Mingrong

AU - Bhagavathula, Akshaya Srikanth

AU - Ali Aldhaleei, Wafa

AU - Clark, Cain

AU - Huo, Zongwei

N1 - NOTICE: this is the author’s version of a work that was accepted for publication in European Journal of Pharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in European Journal of Pharmacology, 883, (2020) DOI: 10.1016/j.ejphar.2020.173382 © 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

PY - 2020/9/15

Y1 - 2020/9/15

N2 - Microvascular invasion (MVI) is an important predictor of metastatic tumour recurrence and is associated with adverse outcomes and poor prognosis in Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. The association between varying regimens of anti-viral drugs with the incidence of MVI in HBV-related HCC has been demonstrated, however, no meta-analysis of the available data has been conducted. Therefore, the current study sought to evaluate the association of preoperative antiviral therapy with incidence of microvascular invasion in HCC hepatitis virus patients. A systematic search of the literature was performed in MEDLINE/PubMed, Web of Science (WoS), and Scopus, up to January 2020. A random-effects model was used to estimate pooled odds ratios (ORs). Overall, six studies, with 4988 patients, met our inclusion criteria. The pooled OR of MVI in the patients who had preoperative antiviral therapy versus the patients who did not have antiviral therapy was; OR: 0.60, 95% Confidence Interval (CI): 0.49–0.73; I 2 = 25%. In this study, a significant reduction in the OR of MVI was evident in patients who had anti-viral therapy.

AB - Microvascular invasion (MVI) is an important predictor of metastatic tumour recurrence and is associated with adverse outcomes and poor prognosis in Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. The association between varying regimens of anti-viral drugs with the incidence of MVI in HBV-related HCC has been demonstrated, however, no meta-analysis of the available data has been conducted. Therefore, the current study sought to evaluate the association of preoperative antiviral therapy with incidence of microvascular invasion in HCC hepatitis virus patients. A systematic search of the literature was performed in MEDLINE/PubMed, Web of Science (WoS), and Scopus, up to January 2020. A random-effects model was used to estimate pooled odds ratios (ORs). Overall, six studies, with 4988 patients, met our inclusion criteria. The pooled OR of MVI in the patients who had preoperative antiviral therapy versus the patients who did not have antiviral therapy was; OR: 0.60, 95% Confidence Interval (CI): 0.49–0.73; I 2 = 25%. In this study, a significant reduction in the OR of MVI was evident in patients who had anti-viral therapy.

KW - Anti-viral therapy

KW - Hepatitis B

KW - Hepatocellular carcinoma

KW - Microvascular invasion

UR - http://www.scopus.com/inward/record.url?scp=85088795555&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2020.173382

DO - 10.1016/j.ejphar.2020.173382

M3 - Review article

VL - 883

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

M1 - 173382

ER -

Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A Meta-Analysis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this